|
|
![]() | ![]() | ![]() | ![]() |
| |||||||||
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Alpha
4 Integrin
Our therapeutic strategy for treating autoimmune and other
diseases is to identify mechanisms common to these diseases and
develop novel therapeutics that stop the underlying causes of
disease. Alpha 4 integrin is a protein expressed by immune cells
that allows those cells to leave the bloodstream and invade
target tissues. Blocking alpha 4 integrin stops immune cells
from entering tissues.
Since first publishing the hypothesis concerning the therapeutic
potential of blocking alpha 4 integrin in 1992, our scientists
have been expanding and refining our understanding of how cells
enter tissues. Through this deep understanding, we have
developed small molecules that can selectively block particular
alpha 4 integrin interactions.
We have advanced a number of compounds in this area. ELND002 is
currently being studied for MS and oncology, and ELND004 is
currently being studied for ulcerative colitis and Crohns
disease.
|
| |||||||